Leukemia, Myeloid: all 2,432 studies

Page 14 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid LeukemiaCompletedNCT03234985
• Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy DonorsTerminatedNCT03233074
• Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT03228303Early Phase 1
• Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.TerminatedNCT03218683Phase 1
• Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.TerminatedNCT03217838Phase 1
• Low-dose Dasatinib as First-line Treatment for Chronic Myeloid LeukemiaStatus unknownNCT03216070Phase 4
• Myeloid Derived Suppressor Cells and Chronic Myeloid LeukemiaStatus unknownNCT03214718Not applicable
• iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)WithdrawnNCT03207334Phase 2
• Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML PatientsStatus unknownNCT03205267Phase 2
• Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid LeukaemiaCompletedNCT03197714Phase 1
• Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous LineageCompletedNCT03194932Phase 1
• Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03194685Phase 1
• Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT03181815Phase 2
• The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
• Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML PatientsStatus unknownNCT03150134Phase 4
• Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)Status unknownNCT03148197
• Study of AMV564 in Patients With AMLCompletedNCT03144245Phase 1
• Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaStatus unknownNCT03131986
• BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)CompletedNCT03127735Phase 1
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT03126864Phase 1
• A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)TerminatedNCT03125876Phase 1
• Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03125239Phase 1
• ENDURE - Efficacy and Safety of AOP2014 With CML Patients in RemissionCompletedNCT03117816Phase 3
• Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCTStatus unknownNCT03114670Phase 1
• An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)No longer availableNCT03114228
• Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyTerminatedNCT03108911Phase 2
• A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1
• Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
• Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaStatus unknownNCT03083054Phase 1/2
• Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AMLCompletedNCT03081780Phase 1
• High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AMLStatus unknownNCT03080922Phase 1/2
• The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal KaryotypeStatus unknownNCT03080766Phase 2
• Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
• Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid LeukemiaStatus unknownNCT03075969
• Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Approved for marketingNCT03070093
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
• Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMTWithdrawnNCT03066466Phase 3
• STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive ChemotherapyCompletedNCT03063944Phase 1
• A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDSWithdrawnNCT03059615Phase 2
• A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid LeukemiaStatus unknownNCT03053206Phase 2
• Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart ReviewCompletedNCT03047083
• Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML PatientsStatus unknownNCT03045627Phase 2
• Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United StatesCompletedNCT03045120
• Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid LeukemiaCompletedNCT03035422Not applicable
• A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)CompletedNCT03030612Phase 1/2
• Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03027102Phase 1
• Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)Status unknownNCT03026842Phase 4
• Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AMLStatus unknownNCT03023384
• CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
• Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPYTerminatedNCT02992860Phase 2
• Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT02985372Phase 3
• Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedNCT02979366Phase 1
• Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in JordanCompletedNCT02977312
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AMLStatus unknownNCT02944162Phase 1/2
• Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+CompletedNCT02936089Not applicable
• PreventiOn of DYSbioSis Complications With Autologous FMT in AML PatientsCompletedNCT02928523Phase 1/2
• Beat AML Core StudyCompletedNCT02927106
• Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AMLCompletedNCT02926586Phase 4
• Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSWithdrawnNCT02923986Phase 1/2
• A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid TreatmentCompletedNCT02921815
• Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedNCT02920541Phase 1
• Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
• Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT02909972Phase 1
• Invasives Aspergillosis in Acute Myeloid LeukemiaCompletedNCT02900430
• Transfusion in Adult Acute Myeloid LeukemiaCompletedNCT02899767
• Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownNCT02899286Phase 2
• Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid LeukemiaCompletedNCT02896829
• Preparatory Work to Assess Adherence to Oral ChemotherapyCompletedNCT02895542
• Infection and Tumour Antigen Cellular TherapyStatus unknownNCT02895412Phase 1
• A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedNCT02892318Phase 1
• An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the NetherlandsCompletedNCT02891551
• Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AMLCompletedNCT02891278Phase 1
• Dasatinib Holiday for Improved TolerabilityCompletedNCT02890784Phase 3
• Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
• Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL GeneStatus unknownNCT02885766Phase 1/2
• Vitro Study of Tigecycline to Treat Chronic Myeloid LeukemiaStatus unknownNCT02883036
• King's Invasive Aspergillosis Study IICompletedNCT02875743Phase 4
• Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AMLTerminatedNCT02875093Phase 1
• MRD-directed Therapy for Low-risk and Intermediate-risk AML.CompletedNCT02870777Phase 2/3
• Regional Central Database Recording of Chronic Myeloid LeukemiaStatus unknownNCT02869256
• A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02864290Phase 1
• Reflexology: An Intervention for Acute Myeloid Leukemia(AML) PatientsStatus unknownNCT02863302Not applicable
• Role of PTK-7 in Acute Myeloid LeukemiasCompletedNCT02860793Not applicable
• A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT02859948Phase 1
• Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid LeukemiaCompletedNCT02856204
• Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML PatientsWithdrawnNCT02856178Phase 1/2
• A Safety Study of SGN-CD123A in Patients With Acute Myeloid LeukemiaTerminatedNCT02848248Phase 1
• Optimal Treatment Strategy Based on for Pediatric AMLStatus unknownNCT02848183Phase 2
• Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the ElderlyCompletedNCT02845232
• Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid LeukaemiaCompletedNCT02844257
• Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid LeukemiaCompletedNCT02844218
• Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase InhibitorCompletedNCT02842333Not applicable
• Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)CompletedNCT02842320Not applicable
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid LeukemiaCompletedNCT02842112
• A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic SyndromesTerminatedNCT02841540Phase 1
• A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02835729Phase 1
• Microtransplantation in Older Patients With Acute Myeloid LeukemiaCompletedNCT02831192Phase 2
• Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2

← Leukemia, Myeloid overview